Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36008722

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Nat Med
Publication date
2022 Nov
First author
Gogishvili M

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Gogishvili M
      type
      Author
    2. name
      Melkadze T
      type
      Author
    3. name
      Makharadze T
      type
      Author
    4. name
      Giorgadze D
      type
      Author
    5. name
      Dvorkin M
      type
      Author
    6. name
      Penkov K
      type
      Author
    7. name
      Laktionov K
      type
      Author
    8. name
      Nemsadze G
      type
      Author
    9. name
      Nechaeva M
      type
      Author
    10. name
      Rozhkova I
      type
      Author
    11. name
      Kalinka E
      type
      Author
    12. name
      Gessner C
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Gogishvili M
      type
      Author
    2. name
      Melkadze T
      type
      Author
    3. name
      Makharadze T
      type
      Author
    4. name
      Giorgadze D
      type
      Author
    5. name
      Dvorkin M
      type
      Author
    6. name
      Penkov K
      type
      Author
    7. name
      Laktionov K
      type
      Author
    8. name
      Nemsadze G
      type
      Author
    9. name
      Nechaeva M
      type
      Author
    10. name
      Rozhkova I
      type
      Author
    11. name
      Kalinka E
      type
      Author
    12. name
      Gessner C
      type
      Author
    bibliography ids
    1. nci-bib-a13a1073ea4b0a4e65f2293b
    book metadata
    content sha256
    342dbcac6f5dc598f9250a3ceaa2925feb66001732bf903c938d98340fb99156
    document type
    citation
    dois
    1. 10.1038/s41591-022-01977-y
    electronic publication date
    display
    2022 Aug 25
    precision
    day
    year
    2022
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:36008722
    immutable id
    pubmed:36008722@342dbcac6f5dc598f9250a3ceaa2925feb66001732bf903c938d98340fb99156
    journal
    abbreviation
    Nat Med
    issn electronic
    1546-170X
    issn print
    1078-8956
    issue
    11
    name
    Nature medicine
    nlm unique id
    9502015
    pages
    2374-2380
    volume
    28
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      36008722
      provenance
      batch id
      9d150d55960e0c12aada
      provider
      NCBI PubMed ESummary
      record sha256
      a626e8135ed39d67e78fec7ac0a83a2d28a4c4c742aeddd74d49be48c9922389
      response sha256
      2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
      retrieved at
      2026-09-09T23:48:09.820498+00:00
      publication date
      display
      2022 Nov
      precision
      month
      year
      2022
      publication types
      1. Randomized Controlled Trial
      2. Clinical Trial, Phase III
      3. Journal Article
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/36008722/
      title
      Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.

      Preserved source evidence · Not medical advice